A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs OMS 721 (Primary)
- Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis; Membranous glomerulonephritis
- Focus Adverse reactions
- Sponsors Omeros Corporation
- 11 Jan 2018 Planned number of patients changed from 26 to 44.
- 11 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 11 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History